The elderly and OTC labeling information: A randomized controlled experiment test

老年人和非处方药标签信息:随机对照实验测试

基本信息

  • 批准号:
    7475564
  • 负责人:
  • 金额:
    $ 3.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Provided by Applicant): The overall study goal is to understand how the elderly utilize risk information on Over-the-Counter (OTC) package labels to form their overall risk perceptions of using an OTC drug product, and to determine their sources of drug information. This study also examines the effects of the absence and presence of risk labeling information on older adults' OTC decisions. Specifically, study objectives are: (1) to propose a consumer's perceived risk model in evaluating OTC risk labeling information for the use of an OTC product in a particular situation; and (2) to test the model on consumers' overall risk perceptions and information sources. Adapting from the Bettman (1973), and Dowling and Staelin (1994) frameworks in marketing research, perceived risk is proposed to consist of 3 risk components: (a) Product Category Risk (PCR) defined as risk associated with a product class; (b) Product Specific Risk (PSR) defined as risk associated with a specific product's characteristics; and (c) Situation Specific Risk (SSR) defined as risk associated with the user's characteristics. This study will employ a completely randomized controlled 2 x 2 x 2 x 2 factorial design to test the effects of the proposed perceived risk model. There will be 16 treatment groups and 2 control groups. Each treatment is operationalized with the following levels of risk: (1) PCR (low risk = cold products vs. high risk = pain relievers); (2) PSR (low risk = 2 side effects vs. high risk = 4 side effects); (3) SSR (low risk = dry skin vs. high risk = diabetes); and (4) presence of SSR information on label (yes vs. no). There are two dependent variables of interest: (1) overall perceived risk of using the OTC product operationalized as consisting of two dimensions: uncertainty and adverse consequences; and (2) information sources operationalized as the likelihood of searching for additional information beyond the label, and the likelihood of using, trusting, and preferring particular sources of information. A sample of 1,620 subjects will be randomly selected from a national commercial consumer mailing list of U.S. adults aged 65 years and older. An initial pilot study will be conducted in a sample of 612 subjects to test the instrument. Each subject will be randomized to a treatment or control group, and mailed one of the 18 versions of a survey packet depending on their assigned group. Each survey packet will contain a cover letter, a 7-page questionnaire and a prepaid return envelope. Subjects are asked to answer questions on their risk perceptions of using a hypothetical OTC product and the sources they would use for drug information after reading a product label and a health scenario for which the product is to be used. The study is relevant to better understanding how elderly consumers make use of OTC risk labeling information in their OTC decisions in order to improve the quality and safety of OTC medication use by the older adults. Study implications include improving OTC package labeling and developing strategies to correct public misconceptions of OTCs. Furthermore, knowledge of the elderly population's choice of OTC drug information sources would be of help to health care professionals engaged in OTC counseling in better handling of patients' questions and concerns.
描述(由申请人提供):总体研究目标是了解老年人如何利用非处方药(OTC)包装标签上的风险信息形成其使用OTC药品的总体风险认知,并确定其药物信息来源。本研究还探讨了风险标签信息的存在和缺失对老年人OTC决策的影响。具体而言,研究目标是:(1)提出一个消费者的感知风险模型,以评估OTC风险标签信息,在特定情况下使用OTC产品;(2)测试消费者的整体风险感知和信息来源的模型。本文借鉴Bettman(1973)、Dowling和Staelin(1994)的营销研究框架,提出感知风险由三个风险组成:(a)产品类别风险(PCR),定义为与产品类别相关的风险;(B)产品特定风险(PSR),定义为与特定产品特征相关的风险;以及(c)特定情况风险(SSR),定义为与用户特征相关的风险。本研究将采用完全随机对照的2 x 2 x 2 x 2析因设计来检验所提出的感知风险模型的效果。将有16个治疗组和2个对照组。每种治疗的操作风险水平如下:(1)PCR(低风险=感冒产品vs.高风险=止痛药);(2)PSR(低风险= 2个副作用vs.高风险= 4个副作用);(3)SSR(低风险=皮肤干燥vs.高风险=糖尿病);(4)标签上是否存在SSR信息(是vs.否)。有两个相关的因变量:(1)使用OTC产品的总体感知风险,可操作性包括两个维度:不确定性和不良后果;(2)信息来源,可操作性包括搜索标签之外的其他信息的可能性,以及使用、信任和偏好特定信息来源的可能性。将从美国65岁及以上成年人的全国商业消费者邮寄名单中随机选择1,620名受试者。将在612名受试者的样本中进行初步试点研究,以测试该工具。每名受试者将被随机分配到治疗组或对照组,并根据其分配的组邮寄18个版本的调查数据包之一。每个调查包将包含一封求职信,一份7页的问卷和一个预付的回邮信封。要求受试者回答关于他们对使用假设OTC产品的风险感知以及他们在阅读产品标签和使用该产品的健康场景后将使用的药物信息来源的问题。该研究有助于更好地了解老年消费者如何在OTC决策中使用OTC风险标签信息,以提高老年人使用OTC药物的质量和安全性。研究的意义包括改进OTC包装标签和制定策略,以纠正公众对OTC的误解。此外,了解老年人对非处方药信息来源的选择将有助于从事非处方药咨询的医疗保健专业人员更好地处理患者的问题和担忧。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nisaratana Sangasubana其他文献

Nisaratana Sangasubana的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nisaratana Sangasubana', 18)}}的其他基金

The elderly and OTC labeling information: A randomized controlled experiment test
老年人和非处方药标签信息:随机对照实验测试
  • 批准号:
    7267541
  • 财政年份:
    2007
  • 资助金额:
    $ 3.4万
  • 项目类别:

相似国自然基金

OTC通过转录因子Purα上调神经元CaMKKβ表达改善HIBD的机制研究
  • 批准号:
    82301574
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于3D生物打印肝脏模型的UPRmt介导OTC缺乏症继发急性肝衰竭的作用机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
基于佩戴与助听舒适性的OTC助听产品形态设计方法研究
  • 批准号:
    52005498
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
OTC基因突变诱导的细胞应激反应及线粒体应激反应基因的筛选
  • 批准号:
    30671185
  • 批准年份:
    2006
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目
CO2升高对温带森林土壤碳库关键过程机制影响的OTC模拟
  • 批准号:
    90411020
  • 批准年份:
    2004
  • 资助金额:
    110.0 万元
  • 项目类别:
    重大研究计划

相似海外基金

microRNA網羅的検索によるOTC併用中毒の病態解明
通过全面的 microRNA 搜索阐明 OTC 组合中毒的病理学
  • 批准号:
    24K20262
  • 财政年份:
    2024
  • 资助金额:
    $ 3.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a novel OTC naloxone product to be affordably priced and widely accessible
开发一种价格实惠且易于使用的新型非处方纳洛酮产品
  • 批准号:
    10400589
  • 财政年份:
    2021
  • 资助金额:
    $ 3.4万
  • 项目类别:
Optimizing OTC labels for older adults: Empirical evaluation of labels designed to provide older users the information they need to minimize adverse drug events
优化老年人 OTC 标签:对旨在为老年用户提供最大程度减少药物不良事件所需信息的标签进行实证评估
  • 批准号:
    10380635
  • 财政年份:
    2018
  • 资助金额:
    $ 3.4万
  • 项目类别:
Optimizing OTC labels for older adults: Empirical evaluation of labels designed to provide older users the information they need to minimize adverse drug events
优化老年人 OTC 标签:对旨在为老年用户提供最大程度减少药物不良事件所需信息的标签进行实证评估
  • 批准号:
    9912730
  • 财政年份:
    2018
  • 资助金额:
    $ 3.4万
  • 项目类别:
Varenicline OTC Trial on Efficacy and Safety
伐尼克兰非处方药疗效和安全性试验
  • 批准号:
    10174897
  • 财政年份:
    2017
  • 资助金额:
    $ 3.4万
  • 项目类别:
Varenicline OTC Trial on Efficacy and Safety
伐尼克兰非处方药疗效和安全性试验
  • 批准号:
    9356811
  • 财政年份:
    2017
  • 资助金额:
    $ 3.4万
  • 项目类别:
Development of package inserts of OTC medicines based on the idea of engineering and clinical psychology
基于工程学和临床心理学思想的OTC药品说明书开发
  • 批准号:
    15K08106
  • 财政年份:
    2015
  • 资助金额:
    $ 3.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The influence of advertising expression of OTC drugs on decision making process through perceptual risk
非处方药广告表达通过感知风险对决策过程的影响
  • 批准号:
    15K13051
  • 财政年份:
    2015
  • 资助金额:
    $ 3.4万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Functional restoration of OTC deficient primary human hepatocytes in a xenograft model using an AAV vector uniquely configured for impending clinical trial use.
使用专门配置用于即将进行的临床试验的 AAV 载体,在异种移植模型中恢复 OTC 缺陷的原代人肝细胞的功能。
  • 批准号:
    nhmrc : 1080333
  • 财政年份:
    2015
  • 资助金额:
    $ 3.4万
  • 项目类别:
    Project Grants
Celebrity Endorsers in OTC Drug Advertising in Japan: From the Source Credibility Perspective
日本非处方药广告中的名人代言人:从来源可信度角度
  • 批准号:
    26380571
  • 财政年份:
    2014
  • 资助金额:
    $ 3.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了